DK1423384T3 - Pyridinderivater som Raf kinaseinhibitorer - Google Patents

Pyridinderivater som Raf kinaseinhibitorer

Info

Publication number
DK1423384T3
DK1423384T3 DK02779311T DK02779311T DK1423384T3 DK 1423384 T3 DK1423384 T3 DK 1423384T3 DK 02779311 T DK02779311 T DK 02779311T DK 02779311 T DK02779311 T DK 02779311T DK 1423384 T3 DK1423384 T3 DK 1423384T3
Authority
DK
Denmark
Prior art keywords
kinase inhibitors
raf kinase
pyridine derivatives
raf
migraine
Prior art date
Application number
DK02779311T
Other languages
English (en)
Inventor
Mark James Bamford
David Kenneth Dean
Antoinette Naylor
Andrew Kenneth Takle
David Matthew Wilson
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DK1423384T3 publication Critical patent/DK1423384T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Insulating Materials (AREA)
DK02779311T 2001-09-05 2002-09-05 Pyridinderivater som Raf kinaseinhibitorer DK1423384T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0121490.7A GB0121490D0 (en) 2001-09-05 2001-09-05 Ciompounds
PCT/EP2002/009946 WO2003022840A1 (en) 2001-09-05 2002-09-05 Pyridine derivatives as raf kinase inhibitors

Publications (1)

Publication Number Publication Date
DK1423384T3 true DK1423384T3 (da) 2007-09-24

Family

ID=9921558

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02779311T DK1423384T3 (da) 2001-09-05 2002-09-05 Pyridinderivater som Raf kinaseinhibitorer

Country Status (11)

Country Link
US (1) US7452906B2 (da)
EP (1) EP1423384B1 (da)
JP (1) JP2005504794A (da)
AT (1) ATE362929T1 (da)
CY (1) CY1106766T1 (da)
DE (1) DE60220290T2 (da)
DK (1) DK1423384T3 (da)
ES (1) ES2284939T3 (da)
GB (1) GB0121490D0 (da)
PT (1) PT1423384E (da)
WO (1) WO2003022840A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001037835A1 (en) 1999-11-22 2001-05-31 Smithkline Beecham Plc. Novel compounds
DE60103136T2 (de) * 2000-03-06 2004-10-28 Smithkline Beecham Plc, Brentford Imidazolderivate als Raf-Kinase Inhibitoren
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
WO2003022837A1 (en) * 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Heterocycle-carboxamide derivatives as raf kinase inhibitors
EP1480975A2 (en) 2002-02-28 2004-12-01 Astrazeneca AB Chemical compounds
US7473699B2 (en) 2002-02-28 2009-01-06 Astrazeneca Ab 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents
WO2003086467A1 (en) * 2002-04-08 2003-10-23 Smithkline Beecham Corporation Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
US20050250837A1 (en) * 2002-10-18 2005-11-10 D Mello Santosh R Use of C-Raf inhibitors for the treatment of neurodegenerative diseases
US20090264494A1 (en) * 2002-10-18 2009-10-22 Board Of Regents, The University Of Texas System Use of neuroprotective 3-substituted indolone compositions
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
WO2007056625A2 (en) * 2005-11-04 2007-05-18 Smithkline Beecham Corporation Thienopyridine b-raf kinase inhibitors
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CA2716949A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
AR072657A1 (es) 2008-02-29 2010-09-15 Genentech Inc Compuestos inhibidores de raf y metodos para su uso
US20120157451A1 (en) 2009-08-28 2012-06-21 Genentech, Inc Raf inhibitor compounds and methods of use thereof
CA2772071A1 (en) 2009-08-28 2011-03-03 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
JP2013503188A (ja) 2009-08-28 2013-01-31 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害化合物およびその使用方法
CA2772316A1 (en) 2009-08-28 2011-03-03 Array Biopharma Inc. 1h-pyrazolo [3,4-b] pyridine compounds for inhibiting raf kinase
CA2772575A1 (en) 2009-08-28 2011-03-03 Genentech, Inc. Raf inhibitor compounds and methods of use thereof
US20120157453A1 (en) 2009-08-28 2012-06-21 Genentech, Inc. Raf inhibitor compounds and methods of use thereof
JP2013514287A (ja) * 2009-12-17 2013-04-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング スフィンゴシンキナーゼの阻害薬
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
US10668055B2 (en) * 2013-12-20 2020-06-02 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of ERK and RAF inhibitors
WO2018125983A1 (en) 2016-12-30 2018-07-05 Mitobridge, Inc. Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA945363B (en) 1993-07-21 1995-03-14 Smithkline Beecham Corp Novel compounds
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
WO2002024680A1 (en) * 2000-09-21 2002-03-28 Smithkline Beecham P.L.C. Imidazole derivatives as raf kinase inhibitors

Also Published As

Publication number Publication date
EP1423384A1 (en) 2004-06-02
WO2003022840A1 (en) 2003-03-20
PT1423384E (pt) 2007-08-24
EP1423384B1 (en) 2007-05-23
DE60220290T2 (de) 2008-01-31
GB0121490D0 (en) 2001-10-24
ES2284939T3 (es) 2007-11-16
ATE362929T1 (de) 2007-06-15
US7452906B2 (en) 2008-11-18
CY1106766T1 (el) 2012-05-23
JP2005504794A (ja) 2005-02-17
DE60220290D1 (de) 2007-07-05
US20040235843A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
DK1318992T3 (da) Imidazolderivater som Raf-kinaseinhibitorer
DK1423384T3 (da) Pyridinderivater som Raf kinaseinhibitorer
LTPA2019511I1 (lt) Rapamicino darinys, skirtas plaučių vėžio gydymui
ATE408601T1 (de) Fredericamycin-derivate
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
WO2003080582A3 (de) Fredericamycin-derivate
NO20082414L (no) Inhibitorer av AKT-aktivitet
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
AU2003226572A1 (en) Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
NO20070782L (no) Tetrapeptidanaloger.
BRPI0411365A (pt) derivados de aminopiridina
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
ATE386034T1 (de) Pyrazoloisoquinolinenderivaten als kinase inhibitoren
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
NO20053356L (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
ATE517896T1 (de) P38-kinase-inhibitoren
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
EA200400235A1 (ru) Комбинированная терапия для лечения рака
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer